| Product |
Abuse-deterrent property |
FDA approval date |
Sponsor Company |
| Oxycontin®
(oxycodone CR Tab)† |
• Mechanical resistance
• Gelling in solvents
|
April 2010
(original formulation: December 1995) |
Purdue Pharma |
| Nucynta® ER
(tapentadol ER tab) |
• Mechanical resistance
|
August 2011 |
Johnson & Johnson/ Janssen Pharmaceuticals |
| Exaglo®
(hydromorphone ER tab) |
• OROS technology, hard outer shell
• Gelling in solvents
|
March 2010 |
Mallinckrodt |
| Opana® ER
(oxymorphone ER tab) |
• Crush resistant
• “Intac technology” byGrunenthal
|
December 2011 |
Endo Pharmaceuticals |
| Oxecta®
(oxycodone tab) |
• Gels in liquid
• Nasal irritant
• “Aversion technology” byAcura Pharmaceuticals
|
June 2011 |
Pfizer Inc. (formerly King Pharmaceuticals) |
| Embeda™
(morphine/naltrexone ER cap) |
• Mixed agonist/antagonist
• Sequestered antagonist
|
August 2009
(Voluntarily Recalled Mar. 2011) |
Pfizer Inc. (formerly King Pharmaceuticals) |
CR, controlled release; ER, extended release; 